Imprimis Pharmaceutical Inc. launch its new Simple drops glaucoma drops at the American Society of Cataract and Refractive Surgery 2017 meeting at the Los Angeles Convention Center this month.
"We believe our Simple drops portfolio gives us a unique advantage in the marketplace because they have been design to help improve compliance by reducing the number of drops patients administer daily," Imprimis CEO Mark Baum said.
Glaucoma makes up a huge portion of the opthalmic market in the U.S., over $2 billion annually.
Baum said the internal team of sales managers would be collaborating with Precision Labs, in the hopes of distributing the treatment throughout the Midwest.
Alerts Sign-up